Header Logo

Connection

PETER HOTEZ to Vaccines

Back to Details
This is a "connection" page, showing publications PETER HOTEZ has written about Vaccines.
PETER HOTEZ
Connection Strength
19.850
Vaccines
  1. Vaccines in a time of global boiling and megacities. Trends Parasitol. 2025 Mar; 41(3):167-169.
    View in: PubMed
    Score: 0.635
  2. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.605
  3. Vaccine value profile for Hookworm. Vaccine. 2024 07 25; 42(19 Suppl 1):S25-S41.
    View in: PubMed
    Score: 0.582
  4. Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis. Vaccine. 2023 11 03; 41 Suppl 2:S176-S179.
    View in: PubMed
    Score: 0.581
  5. Vaccine Preventable Disease and Vaccine Hesitancy. Med Clin North Am. 2023 Nov; 107(6):979-987.
    View in: PubMed
    Score: 0.571
  6. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.555
  7. COVID-19 vaccines: the imperfect instruments of vaccine diplomacy. J Travel Med. 2022 12 27; 29(8).
    View in: PubMed
    Score: 0.550
  8. Malnutrition vaccines for an imminent global food catastrophe. Trends Pharmacol Sci. 2022 12; 43(12):994-997.
    View in: PubMed
    Score: 0.539
  9. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.532
  10. Communicating science and protecting scientists in a time of political instability. Trends Mol Med. 2022 03; 28(3):173-175.
    View in: PubMed
    Score: 0.516
  11. The yin and yang of human soil-transmitted helminth infections. Int J Parasitol. 2021 12; 51(13-14):1243-1253.
    View in: PubMed
    Score: 0.509
  12. Immunizations and vaccines: a decade of successes and reversals, and a call for 'vaccine diplomacy'. Int Health. 2019 09 02; 11(5):331-333.
    View in: PubMed
    Score: 0.437
  13. "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action". Hum Vaccin Immunother. 2019; 15(10):2235-2242.
    View in: PubMed
    Score: 0.433
  14. America and Europe's new normal: the return of vaccine-preventable diseases. Pediatr Res. 2019 06; 85(7):912-914.
    View in: PubMed
    Score: 0.422
  15. Advancing the Development of a Human Schistosomiasis Vaccine. Trends Parasitol. 2019 02; 35(2):104-108.
    View in: PubMed
    Score: 0.414
  16. Minutes to midnight: Turning back the Doomsday Clock through neglected disease vaccine diplomacy. PLoS Negl Trop Dis. 2018 09; 12(9):e0006676.
    View in: PubMed
    Score: 0.409
  17. Vaccines Hesitancy and the Dermatologist. Skinmed. 2018; 16(4):219-221.
    View in: PubMed
    Score: 0.403
  18. The global fight to develop antipoverty vaccines in the anti-vaccine era. Hum Vaccin Immunother. 2018; 14(9):2128-2131.
    View in: PubMed
    Score: 0.399
  19. Russian-United States vaccine science diplomacy: Preserving the legacy. PLoS Negl Trop Dis. 2017 May; 11(5):e0005320.
    View in: PubMed
    Score: 0.374
  20. Developing and financing neglected disease vaccines in our new era of "blue marble health" and the anthropocene epoch. Vaccine. 2017 09 25; 35(40):5403-5405.
    View in: PubMed
    Score: 0.368
  21. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.348
  22. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.345
  23. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.332
  24. Combating the next lethal epidemic. Science. 2015 Apr 17; 348(6232):296-7.
    View in: PubMed
    Score: 0.323
  25. The Human Hookworm Vaccine. Vaccine. 2013 Apr 18; 31 Suppl 2:B227-32.
    View in: PubMed
    Score: 0.281
  26. Vaccinomics for the major blood feeding helminths of humans. OMICS. 2011 Sep; 15(9):567-77.
    View in: PubMed
    Score: 0.248
  27. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood). 2011 Jun; 30(6):1080-7.
    View in: PubMed
    Score: 0.247
  28. New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis. 2011; 5(5):e1133.
    View in: PubMed
    Score: 0.247
  29. Vaccines to combat the neglected tropical diseases. Immunol Rev. 2011 Jan; 239(1):237-70.
    View in: PubMed
    Score: 0.240
  30. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol. 2010 Nov; 8(11):814-26.
    View in: PubMed
    Score: 0.237
  31. Peace through vaccine diplomacy. Science. 2010 Mar 12; 327(5971):1301.
    View in: PubMed
    Score: 0.227
  32. Neglected tropical disease vaccines. Biologicals. 2009 Jun; 37(3):160-4.
    View in: PubMed
    Score: 0.212
  33. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines. 2008 Aug; 7(6):745-52.
    View in: PubMed
    Score: 0.203
  34. Hookworm vaccines. Clin Infect Dis. 2008 Jan 15; 46(2):282-8.
    View in: PubMed
    Score: 0.195
  35. Use of the air pouch model to investigate immune responses to a hookworm vaccine containing the Na-ASP-2 protein in rats. Parasite Immunol. 2008 Jan; 30(1):53-6.
    View in: PubMed
    Score: 0.195
  36. Hookworm vaccines: past, present, and future. Lancet Infect Dis. 2006 Nov; 6(11):733-41.
    View in: PubMed
    Score: 0.180
  37. The antipoverty vaccines. Vaccine. 2006 Jul 26; 24(31-32):5787-99.
    View in: PubMed
    Score: 0.174
  38. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines. 2006 Apr; 5(2):189-98.
    View in: PubMed
    Score: 0.173
  39. Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm Ancylostoma caninum. Infect Immun. 2005 Oct; 73(10):6903-11.
    View in: PubMed
    Score: 0.167
  40. Vaccine value profile for schistosomiasis. Vaccine. 2025 Oct 03; 64:126020.
    View in: PubMed
    Score: 0.153
  41. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 11; 17(11):e0011519.
    View in: PubMed
    Score: 0.146
  42. Factors, enablers and challenges for COVID-19 vaccine development. BMJ Glob Health. 2023 06; 8(6).
    View in: PubMed
    Score: 0.142
  43. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob Health. 2023 06; 8(6).
    View in: PubMed
    Score: 0.142
  44. Progress in vaccine development for infectious diseases-a Keystone Symposia report. Ann N Y Acad Sci. 2023 06; 1524(1):65-86.
    View in: PubMed
    Score: 0.140
  45. Vaxi-DL: An Artificial Intelligence-Enabled Platform for Vaccine Development. Methods Mol Biol. 2023; 2673:305-316.
    View in: PubMed
    Score: 0.138
  46. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-na?ve adults. Vaccine. 2022 10 06; 40(42):6084-6092.
    View in: PubMed
    Score: 0.135
  47. Creation of a Global Vaccine Risk Index. PLoS One. 2022; 17(8):e0272784.
    View in: PubMed
    Score: 0.134
  48. Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet. 2022 08 13; 400(10351):535-538.
    View in: PubMed
    Score: 0.133
  49. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Front Cell Infect Microbiol. 2022; 12:869039.
    View in: PubMed
    Score: 0.131
  50. Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. Comput Biol Med. 2022 06; 145:105401.
    View in: PubMed
    Score: 0.130
  51. Vaccines as instruments of foreign policy. The new vaccines for tropical infectious diseases may have unanticipated uses beyond fighting diseases. EMBO Rep. 2001 Oct; 2(10):862-8.
    View in: PubMed
    Score: 0.126
  52. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
    View in: PubMed
    Score: 0.126
  53. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.126
  54. COVID-19 and the rise of anti-science. Expert Rev Vaccines. 2021 03; 20(3):227-229.
    View in: PubMed
    Score: 0.121
  55. NTDs in the 2020s: An epic struggle of effective control tools versus the Anthropocene. PLoS Negl Trop Dis. 2020 09; 14(9):e0007872.
    View in: PubMed
    Score: 0.118
  56. Anti-science extremism in America: escalating and globalizing. Microbes Infect. 2020 Nov - Dec; 22(10):505-507.
    View in: PubMed
    Score: 0.118
  57. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2021 02; 21(2):275-285.
    View in: PubMed
    Score: 0.117
  58. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.113
  59. The 2016 California policy to eliminate nonmedical vaccine exemptions and changes in vaccine coverage: An empirical policy analysis. PLoS Med. 2019 12; 16(12):e1002994.
    View in: PubMed
    Score: 0.112
  60. The rise or fall of neglected tropical diseases in East Asia Pacific. Acta Trop. 2020 Feb; 202:105182.
    View in: PubMed
    Score: 0.110
  61. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Negl Trop Dis. 2019 09; 13(9):e0007730.
    View in: PubMed
    Score: 0.110
  62. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.109
  63. The Salzburg Statement on Vaccination Acceptance. J Health Commun. 2019; 24(5):581-583.
    View in: PubMed
    Score: 0.108
  64. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.107
  65. Science in the fight to uphold the rights of children. PLoS Biol. 2018 09; 16(9):e3000010.
    View in: PubMed
    Score: 0.102
  66. Cutaneous and subcutaneous granulomata formation in mice immunized and challenged with third-stage infective hookworm (Ancylostoma caninum) larvae. Acta Trop. 1998 Jun; 69(3):229-38.
    View in: PubMed
    Score: 0.100
  67. The poverty-related neglected diseases: Why basic research matters. PLoS Biol. 2017 Nov; 15(11):e2004186.
    View in: PubMed
    Score: 0.096
  68. Vaccines for hookworm infection. Pediatr Infect Dis J. 1997 Oct; 16(10):935-40.
    View in: PubMed
    Score: 0.096
  69. Onchocerca volvulus: The Road from Basic Biology to a Vaccine. Trends Parasitol. 2018 01; 34(1):64-79.
    View in: PubMed
    Score: 0.096
  70. Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. Infect Immun. 2017 09; 85(9).
    View in: PubMed
    Score: 0.095
  71. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
    View in: PubMed
    Score: 0.094
  72. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis. 2017 02; 11(2):e0005385.
    View in: PubMed
    Score: 0.092
  73. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.092
  74. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis. 2016 07; 10(7):e0004797.
    View in: PubMed
    Score: 0.088
  75. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.086
  76. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
    View in: PubMed
    Score: 0.086
  77. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol. 2014 Aug; 44(9):637-46.
    View in: PubMed
    Score: 0.076
  78. Global progress towards eliminating gastrointestinal helminth infections. Curr Opin Gastroenterol. 2014 Jan; 30(1):18-24.
    View in: PubMed
    Score: 0.074
  79. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2342-50.
    View in: PubMed
    Score: 0.072
  80. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2351-61.
    View in: PubMed
    Score: 0.072
  81. New vaccines for neglected parasitic diseases and dengue. Transl Res. 2013 Sep; 162(3):144-55.
    View in: PubMed
    Score: 0.070
  82. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas. Adv Exp Med Biol. 2013; 764:1-12.
    View in: PubMed
    Score: 0.069
  83. Molecular mechanisms of hookworm disease: stealth, virulence, and vaccines. J Allergy Clin Immunol. 2012 Jul; 130(1):13-21.
    View in: PubMed
    Score: 0.067
  84. Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine. 2011 May 09; 29(20):3686-94.
    View in: PubMed
    Score: 0.061
  85. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. J Infect Dis. 2010 May 15; 201(10):1561-9.
    View in: PubMed
    Score: 0.057
  86. Modelling heterogeneity and the impact of chemotherapy and vaccination against human hookworm. J R Soc Interface. 2008 Nov 06; 5(28):1329-41.
    View in: PubMed
    Score: 0.052
  87. Reinventing Guantanamo: from detainee facility to Center for Research on Neglected Diseases of Poverty in the Americas. PLoS Negl Trop Dis. 2008 Feb 27; 2(2):e201.
    View in: PubMed
    Score: 0.049
  88. Protective immunity elicited by ultraviolet-irradiated third-stage infective hookworm (Necator americanus and Ancylostoma caninum) larvae in mice and hamsters. Southeast Asian J Trop Med Public Health. 2006 Sep; 37(5):885-95.
    View in: PubMed
    Score: 0.044
  89. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J. 2005 Oct; 19(12):1743-5.
    View in: PubMed
    Score: 0.041
  90. Immunogenicity of the hookworm Na-ASP-2 vaccine candidate: characterization of humoral and cellular responses after vaccination in the Sprague Dawley rat. Hum Vaccin. 2005 May-Jun; 1(3):123-8.
    View in: PubMed
    Score: 0.041
  91. Hookworm: "the great infection of mankind". PLoS Med. 2005 Mar; 2(3):e67.
    View in: PubMed
    Score: 0.040
  92. X-ray structure of Na-ASP-2, a pathogenesis-related-1 protein from the nematode parasite, Necator americanus, and a vaccine antigen for human hookworm infection. J Mol Biol. 2005 Feb 25; 346(3):801-14.
    View in: PubMed
    Score: 0.040
  93. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024 07; 24(7):760-774.
    View in: PubMed
    Score: 0.037
  94. Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression. Int J Parasitol. 2003 May; 33(5-6):621-40.
    View in: PubMed
    Score: 0.035
  95. Cutaneous and subcutaneous mast cell and eosinophil responses after challenge in mice vaccinated with living infective third-stage hookworm larvae. Chin Med J (Engl). 1999 Nov; 112(11):1020-3.
    View in: PubMed
    Score: 0.028
  96. What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks? J Infect Dis. 2019 08 09; 220(6):920-931.
    View in: PubMed
    Score: 0.027
  97. Histochemical alterations of infective third-stage hookworm larvae (L3) in vaccinated mice. Southeast Asian J Trop Med Public Health. 1999 Jun; 30(2):356-64.
    View in: PubMed
    Score: 0.027
  98. Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas. Emerg Infect Dis. 2019 04; 25(4):625-632.
    View in: PubMed
    Score: 0.027
  99. IgG Induced by Vaccination With Ascaris suum Extracts Is Protective Against Infection. Front Immunol. 2018; 9:2535.
    View in: PubMed
    Score: 0.026
  100. Protective immunity in mice elicited by living infective third-stage hookworm larvae (Shanghai strain of Ancylostoma caninum). Chin Med J (Engl). 1998 Jan; 111(1):43-8.
    View in: PubMed
    Score: 0.024
  101. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 2009 Sep; 23(9):3007-19.
    View in: PubMed
    Score: 0.013
  102. Variation between ASP-1 molecules from Ancylostoma caninum in China and the United States. J Parasitol. 2000 Feb; 86(1):181-5.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.